Priyanka Bikkina
Endocrinology, Diabetes & Metabolism · Portage, MINPI 1023437043
Payments from drug & device makers
Across 109 payments — averaging $17.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insulet Corporation$232
- Novartis$180
- Lilly USA, LLC$147
- Novo Nordisk$145
- Dexcom, Inc.$124
- Amgen$120
- plus $934 from 25 others
What the payments were for
- Food & beverage$1,81496%
- Education$694%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insulet Corporation | 8 | $232 |
| Novartis | 16 | $180 |
| Lilly USA, LLC | 10 | $147 |
| Novo Nordisk | 9 | $145 |
| Dexcom, Inc. | 7 | $124 |
| Amgen(2 entities) | 7 | $120 |
| Abbott | 6 | $114 |
| Tandem Diabetes Care, Inc. | 7 | $89 |
| Xeris Pharmaceuticals, Inc. | 5 | $87 |
| Mannkind Corporation | 3 | $84 |
| Medtronic | 3 | $73 |
| Bayer | 3 | $43 |
| Pfizer | 2 | $39 |
| Neurocrine Biosciences, Inc. | 1 | $36 |
| Sequel Med Tech, LLC | 2 | $35 |
| Corcept Therapeutics | 2 | $34 |
| Companion Medical, Inc. | 2 | $34 |
| Sanofi-aventis U.S. LLC | 2 | $29 |
| Amneal Pharmaceuticals LLC | 2 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $26 |
| IBSA Pharma Inc. | 1 | $23 |
| Merck | 1 | $23 |
| Zealand Pharma US, Inc. | 1 | $20 |
| BETA Bionics, Inc. | 1 | $20 |
| AbbVie | 1 | $16 |
| Ascensia Diabetes Care US Inc. | 1 | $15 |
| Recordati_rare_diseases_inc. | 1 | $15 |
| Radius Health, Inc. | 1 | $15 |
| Cequr Corporation | 1 | $13 |
| Ipsen Biopharmaceuticals, Inc | 1 | $12 |
| Amarin Pharma, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Omnipod$127
How this compares
$1,883 in reported general payments places this provider in the 50th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.
See all endocrinology, diabetes & metabolism providers in Michigan →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 191 | $263,437 |
| JardianceEmpagliflozin | 134 | $135,210 |
| OzempicSemaglutide | 77 | $132,927 |
| TrulicityDulaglutide | 92 | $109,030 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 24 | $73,329 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 55 | $68,931 |
| Tresiba Flextouch U-200Insulin Degludec | 24 | $33,914 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 104 | $15,486 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 35 | $15,405 |
| FarxigaDapagliflozin Propanediol | 17 | $15,285 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 12 | $14,339 |
| Tresiba Flextouch U-100Insulin Degludec | 21 | $11,530 |
| NovologInsulin Aspart | 37 | $10,682 |
| HumalogInsulin Lispro | 28 | $9,856 |
| Repatha SureclickEvolocumab | 18 | $9,592 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Lyumjev, Insulin Lispro | $147 | $389,473339 claims |
| Novo NordiskOzempic, Xultophy 100-3.6, Novolog | $145 | $157,948126 claims |
| MerckJanuvia | $23 | $8,68513 claims |
| Sanofi-aventis U.S. LLCLantus | $29 | $6,32538 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $28 | $5,271391 claims |
| AbbVieSynthroid | $16 | $4,46458 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.
Other endocrinology, diabetes & metabolism in Portage
- Tobias ElseAnn Arbor$3.5M
- Elif OralAnn Arbor$2.9M
- Jamal HammoudFlint$2.6M
- Lowell SchmeltzFarmington Hills$2.3M
- George GrunbergerBloomfield Hills$1.9M
- Richard AuchusAnn Arbor$1.3M
- Ariel BarkanAnn Arbor$553K
- Gary EdelsonFarmington Hills$503K
- Michael BrennanSaint Clair Shores$433K
- Abdulsalam Al KassabRochester Hills$351K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.